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Dear Editor,
We appreciate the comments on our recent review article
about strategies to enhance access to diagnosis and treatment
for Chagas disease patients [1,2]. We also appreciate the
opportunity to respond to them, and expand the discussion
on this crucial topic given that it is estimated that no more
than 1% of the infected population by Trypanosoma cruzi (of
~7 million people) ultimately get access to treatment [3].
The letter comments mainly refer to two of the sections
of the review article: diagnostics to detect the infection
(section 2), and treatment opportunities and possibilities
(section 7).
Regarding the first, we deeply agree with the concerns of
the letter authors on the reduced access to Polymerase Chain
Reaction (PCR) and conventional serology (ELISA) tests for the
diagnosis of Chagas disease in many areas where the disease
is highly endemic and only poorly equipped laboratories are
available. In fact, our team at ISGlobal is working at present in
a research line which aims to show that the use of alternative
diagnostic methodologies, easier to use in those regions, can
indeed substitute conventional diagnostics [4,5]. This is, in our
opinion, the most urgent necessity in relation to Chagas dis-
ease diagnostics at the moment: validation and implementa-
tion of rapid diagnostic tests (RDTs) to diagnose chronic
infections, and easy-to-use molecular tools such as loop
mediated isothermal amplification (LAMP) to early detect con-
genital transmission events [6].
From our experience, the use of parasitological methods in
regions with poorly equipped laboratories is primarily done for
the detection of acute infections (such as congenital ones).
However, without an appropriate screening of the mothers
and considering that the acute stage of Chagas disease is
usually asymptomatic or can be confounded with other dis-
eases and go unnoticed, diagnosis is normally achieved at the
chronic stage, either in the context of a screening campaign or
because there is a clinical suspicion of the infection. By then
parasitemia is low and intermittent and direct diagnosis is
useless [7]; even if more sensitive molecular detection tools
are used as the letter authors point out. Furthermore, it must
be stressed that although finding trypomastigotes in a blood
preparation is indeed a definitive proof of infection, it is no
less true that the sensitivity of direct parasitological techni-
ques is low and the algorithm to diagnose a congenital trans-
mission, besides one or two micromethods, does comprise as
well the serological determination of anti-T. cruzi immunoglo-
bulins once maternal antibodies have waned [7]. So there is
yet the urgency for a more sensitive and timely diagnosis of
congenital (acute) infections as a very large percentage of
children born to seropositive mothers are lost to follow-up
and may only get diagnosed as chronically infected adults.
In truth, serological tests and PCRmethods are more effective
diagnostics than direct observation of circulating parasites.
Current molecular amplification protocols have been developed
taking into account T. cruzi genetic diversity [5,6]. In relation to
serology-based diagnosis, cross-reactivity with host-derivedmoi-
eties and antigens of related parasites (e.g. Leishmania spp.) has
been described before [8]. But nowadays there are many com-
mercially available tests based on recombinant T. cruzi antigens
that have greatly overcome those limitations, as it can be
observed in that very same reference [8]. In fact, as the letter
authors comment, the agreement of two tests based on distinct
antigen sets is still required for conclusive diagnosis of Chagas
disease. This is, despite improvements in their performance,
a practice that imposes extra costs in the diagnosis of the infec-
tion, and often entails delays in the turnaround of results with
the risk of loss-to-treatment of infected subjects. Therefore con-
sidering the performance of presently available diagnostics,
rather than suggesting further confirmation with immunoblots
and PCRs, we would suggest to place the focus on the develop-
ment and wider use of point-of-care diagnostics such as RDTs
and LAMP, which would facilitate access to a diagnosis with the
goal to ultimately simplify access to treatment [1].
In contrast we agree with the authors of the letter that the
evaluation of parasite cure might not be the only way to
ascertain therapeutic efficacy. Nonetheless, clear and defined
readouts are required to be able to follow-up treatment
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response in the context of daily clinical management of
patients or during the performance of clinical trials. Since
confirmation of cure is currently difficult to ascertain as ser-
ological reversion can take over a decade to occur and this is
not practical, molecular amplification of parasite DNA is taken
as a surrogate of treatment failure and negative amplification
is considered an indication of therapeutic response [7].
Molecular tools cannot fully assure that the treatment worked
as a relapse may occur at any other time point sampled, so it is
fundamental to develop and validate other biomarkers for the
early assessment of treatment efficacy [9]. But it is understand-
able that if it is the presence of the parasite what is causing
the damage (as it is well acknowledged by now), whatever
intervention that stops or delays the advancement of the
infection (be it chemotherapy, be it a vaccine, or its combina-
tion), will clearly be of benefit to the patients. This can be
monitored to a certain extent with molecular tools, and there
is plenty of evidence currently supporting these arguments
[10–14].
On the other hand, with respect to the comments on
treatment, the use of ‘traditional’ chemotherapy doses and
regimens in clinical trials have been shown to be reasonable
in order to compare them with new drugs under evaluation or
with new regimens and doses of existing ones [11,12,14]. As
for the controversy in the therapeutic effects when late
chronic patients were treated, we are not sure whether the
letter authors refer to the results of the BENEFIT trial or to the
results of any of the other trials they mention (CHAGASAZOL
or STOP-CHAGAS). If they meant the former, then it must be
noted that rather than a cause-effect derived from early or late
chronic infections being treated, the main issue with the
BENEFIT trial design, in our opinion, which coincides with
that expressed by others [15], is that it admitted subjects
with advanced heart tissue damage [1]. We do not find any
controversy related to the results from any of the other trials,
including E1224 [11], where qPCR was the main tool to deter-
mine treatment failure or suggest treatment success at the
particular time point when it was performed. These studies
provided a range of response to the standard benznidazole
treatment of 55% – 85% of the adults chronically infected with
T. cruzi by twelve months post-treatment (see Table 1 in
reference [1]). In light of these results, and with the support
of pre-clinical and pharmacokinetic studies, the administration
of reduced doses and/or alternative regimens of benznidazole
and nifurtimox is being explored [1]. The outcome of these
new trials will determine whether efficacy can be maintained
or even increased and the advent of adverse events reduced,
which would be greatly beneficial to all to-be-treated
patients [1].
Meanwhile, as it has been proved that treatment of women
at child-bearing age does significantly stop the transmission of
congenital Chagas disease [16], and BENEFIT´s main lesson
was that providing treatment to patients with advanced car-
diac damage did not improve their status, administration of
treatment should be done before the appearance of cardiac
complications. Therefore, until new drugs or new regimens of
existing ones are on the table, presently available treatment
must be the prevailing option for those cases either indeter-
minate or with early cardiac involvement [17].
All the former said, we strongly disagree with the letter
closing sentence. It is exactly because of all the aforemen-
tioned arguments that the therapeutic potential of treatment
cannot be considered uncertain anymore. Of course, more
effective and less toxic treatments would be of great impor-
tance and welcomed, especially for the chronic stage of the
disease. But presently available drugs could already make
a difference if access is increased and they would be made
available to many more patients than they are now.
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